Introduction
Pyridoxine dependent epilepsy (PDE) is a rare autosomal neurometabolic disorder with autosomal recessive inheritance characterized by a combination of various seizure types (MIM#266100). In the classical form, seizures are observed within the first month of life, often within hours of birth and are unresponsive to conventional anticonvulsant therapy, but can be controlled with pyridoxine monotherapy. In the atypical form seizures might appear until later in life, sometimes as late as at the age of 3 years of life, and are also pyridoxine dependent [1] .
Mutations in the ALDH7A1 gene, encoding a-aminoadipic semialdehyde dehydrogenase, within the pipecolic acid pathway of lysine catabolism, have been reported to cause this disease in most patients [2] . Up to now, more than 70 ALDH7A1 different pathogenic mutations have been reported in the literature associated with PDE phenotypic spectrum in patients from diverse ethnic backgrounds. Here, we report a Lebanese child with a lateonset form of PDE in whom, we identified by Whole Exome Sequencing (WES) a novel homozygous missense mutation in ALDH7A1.
Case report
The propositus was referred to our institution for genetic examination at the age of 6 years because of developmental delay and intreatable seizures. His parents are first cousins, healthy, such as his 2 sisters. Developmental milestones were slightly delayed as he was able to sit and walk at 9 and 15 months respectively. At 18 months, seizures started in cluster for 4 to 5 days, with 1 to 3 seizures per day, every 4 months. Different antiepileptic drugs were tried, but without being very effective on the crises. He was enrolled in a normal school but had learning difficulties and hyperactivity. During examination, he was cooperative, responding to simple orders and had poor language as he could say only few words. His height was 49 cm, and his head circumference was 52 cm. He had hypertelorism, depressed nasal bridge, bilateral epichanthic folds, prominent ears, and a right simian crease. Neurological, ophthalmological and heart examinations were normal.
An electroencephalogram monitoring revealed posterior temporal sharp waves. The brain magnetic resonance imaging showed Blood sampling and WES were performed after obtaining informed consent, in accordance with the principles of the Declaration of Helsinki. Data analysis was focused on variants within a panel of 280 epilepsy-genes and identified a homozygous missense mutation in ALDH7A1 (NM_001182: c.239T > G, p.V80G) that was not found neither in the in-house Lebanese database, nor in the Exome Aggregation Consortium. The pathogenicity of this novel mutation was substantiated using different bioinformatics prediction softwares, such as: Mutation Taster, SIFT and Polyphen. By Sanger sequencing, we confirmed the presence of the mutation at the homozygous state in the affected patient, and heterozygous state in the parents and the 2 unaffected daughters.
Discussion
Here, we report the identification of a novel homozygous missense mutation in exon 2 of the ALDH7A1 gene, (p.Val80Gly), in a Lebanese patient affected with resistant epilepsy. ALDH7A1 mutations comprise mainly missense, nonsense, and splice site mutations [3] . In literature, most of the reported mutations have been found in exons 5, 6, 9, 11, 14, 15 and 16. No genotypephenotype correlation was noted as the same mutation was showed to cause both cases of classic neonatal-onset form and late-onset cases. As seen in the present case, clinical features of PDE patients are not limited to seizures; many patients have associated neurologic dysfunctions with variety degrees of severity. With this in mind, we can considered that phenotypes can be modified by other factors such as other genes and/or environmental elements [3] .
The treatment consists on high-dose pyridoxine therapy which was started in the present patient leading finally to control seizures. In order, to improve long-term neurodevelopmental outcomes in patients, combined therapy with pyridoxine, arginine supplementation, and dietary lysine restriction is recommended [4] .
WES could be useful for defining an early accurate treatment especially for atypical forms that have been missed due to testing bias. The advent of WES techniques comprise the beginning of a new era, for researches into nearly every complex disorder. With this faster method, researchers will benefit greatly from the ability to determine mutations and put a rapidly clinical diagnosis as well as for PDE and in other diseases where loads of candidate genes and loci caused these disorders.
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